| Size | Price | Stock | Qty |
|---|---|---|---|
| 500g |
|
||
| Other Sizes |
| Targets |
5-Nitroimidazole does not have a defined primary drug target as it is a fragment molecule and chemical reagent rather than a therapeutic agent. However, nitroimidazole derivatives are well-known for their antimicrobial and antiprotozoal activities. The nitro group can be reduced in anaerobic microorganisms to reactive intermediates that damage DNA and other cellular components. This mechanism is the basis for the activity of metronidazole and other nitroimidazole antibiotics. As a fragment molecule, 5-nitroimidazole is used as a scaffold for the development of novel drug candidates targeting various diseases.
|
|---|---|
| ln Vitro |
In the process of creating 1-methyl-2,4,5-trinitroimidazole, 4-nitroimidazole is a necessary step.
In vitro studies have demonstrated that nitroimidazole derivatives exhibit antimicrobial and antiprotozoal activities through nitroreduction to reactive intermediates. 5-Nitroimidazole serves as a core scaffold for the synthesis of bioactive compounds. The compound's activity is related to the presence of the nitro group, which can be reduced in target organisms. As a fragment molecule, it is used in drug discovery to build more complex molecules with enhanced biological activities. The compound's potential as a building block for drug candidates is its primary research value. |
| ln Vivo |
In vivo activity data for 5-Nitroimidazole itself is not available, as the compound is a fragment molecule and chemical reagent rather than a therapeutic agent. However, metronidazole (of which 5-nitroimidazole is an impurity) and other nitroimidazole drugs have well-established in vivo efficacy as antimicrobial and antiprotozoal agents. The nitroimidazole scaffold is a proven pharmacophore for the treatment of anaerobic bacterial and protozoal infections. Drug candidates synthesized using 5-nitroimidazole as a scaffold may be evaluated in animal models.
|
| Enzyme Assay |
Cell-free biochemical assays involving 5-Nitroimidazole typically focus on its use as a fragment or building block in drug discovery rather than as an enzyme inhibitor. In fragment-based drug discovery, a standard protocol involves screening 5-nitroimidazole against target proteins using techniques such as surface plasmon resonance (SPR), NMR spectroscopy, or X-ray crystallography to identify binding interactions. The compound's nitro group can participate in redox reactions, and its imidazole core provides hydrogen bonding and π-stacking interactions. For metronidazole impurity analysis, HPLC methods are used to detect and quantify 5-nitroimidazole. Assays are performed with appropriate controls.
|
| Cell Assay |
Cell-based assays for 5-nitroimidazole derivatives typically evaluate antimicrobial or antiprotozoal activity. A standard protocol involves culturing anaerobic bacteria (e.g., Bacteroides species) or protozoa (e.g., Trichomonas vaginalis) in appropriate media, treating with varying concentrations of the test compound (1-100 μg/mL) for 24-48 hours, and measuring growth inhibition by optical density or colony counting. For cytotoxicity assessment, mammalian cell lines are treated with the compound and cell viability is assessed by MTT or other assays. The compound's activity is dependent on nitroreduction in target organisms.
|
| Animal Protocol |
In vivo studies with 5-nitroimidazole derivatives are typically conducted in animal models of infection. For antimicrobial studies, mice are infected with anaerobic bacteria or protozoa and treated with the test compound by oral or intraperitoneal administration. Efficacy is assessed by measuring pathogen load in tissues or survival. Metronidazole, a related nitroimidazole drug, has well-established in vivo efficacy. For fragment molecules like 5-nitroimidazole, in vivo studies are limited to drug candidates derived from the scaffold.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 5-nitroimidazole is not available, as the compound is a fragment molecule rather than a drug. The molecular weight is 113.08 g/mol. For nitroimidazole drugs such as metronidazole, PK parameters are well characterized. Metronidazole is well absorbed orally, distributes widely to tissues, and is metabolized in the liver. The nitroimidazole scaffold generally confers favorable drug-like properties including moderate polarity and reasonable oral bioavailability.
|
| Toxicity/Toxicokinetics |
Toxicological data for 5-nitroimidazole indicates that it is a potential human carcinogen. This classification is based on the known toxicity of nitroimidazole compounds, which can form reactive intermediates upon reduction. As with all nitro compounds and chemical reagents, standard laboratory safety precautions should be observed when handling this compound. For drug candidates synthesized from this scaffold, comprehensive toxicological evaluation is required as part of the drug development process.
|
| Additional Infomation |
5-Nitroimidazole is a C-nitro compound, which is an imidazole compound with a nitro substituent at the 5-position.
5-Nitroimidazole is a research compound and fragment molecule rather than an approved pharmaceutical agent. No clinical trials or regulatory approvals exist for this compound itself. It is commercially available from various chemical suppliers for research purposes only. The compound's primary value lies in its utility as a fragment molecule and scaffold for molecular splicing, expansion, and modification in drug discovery. It provides a structural foundation and research tool for the design and screening of novel drug candidates. 5-Nitroimidazole is also an impurity of Metronidazole and is used in the synthesis of OLED materials. |
| Molecular Formula |
C3H3N3O2
|
|---|---|
| Molecular Weight |
113.07
|
| Exact Mass |
113.022
|
| CAS # |
3034-38-6
|
| PubChem CID |
18208
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
404.8±18.0 °C at 760 mmHg
|
| Melting Point |
303 °C (dec.)(lit.)
|
| Flash Point |
198.6±21.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
-0.08
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
99.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=[N+](C1=CN=CN1)[O-]
|
| InChi Key |
VYDWQPKRHOGLPA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H3N3O2/c7-6(8)3-1-4-2-5-3/h1-2H,(H,4,5)
|
| Chemical Name |
5-nitro-1H-imidazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.8441 mL | 44.2204 mL | 88.4408 mL | |
| 5 mM | 1.7688 mL | 8.8441 mL | 17.6882 mL | |
| 10 mM | 0.8844 mL | 4.4220 mL | 8.8441 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
